12th International Symposium
ADVANCED
Optimal Therapy. Update
Valencia, 22nd February 2019
OVARIAN CANCER

Andrés Poveda
Initia Oncology, Hospital Quirónsalud, Valencia, Spain
Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

VENUE
Palau de la Música
“Iturbi” Meeting Room
Paseo de la Alameda, 30 · 46023 Valencia, Spain

SYMPOSIUM SECRETARIAT
E-mail: aocsymp2019@doctaforum.com
Phone: +34 913 72 02 03
Web: www.valencia-ovariancancersymp.org

Click here to consult the programme of the symposium.

www.valencia-ovariancancersymp.org
VENUE
Palau de la Música
"Iturbi" Meeting Room
Paseo de la Alameda, 30 · 46023 Valencia, Spain

SYMPOSIUM SECRETARIAT
E-mail: aocsymp2019@doctaforum.com
Phone: +34 913 72 02 03
Web: www.valencia-ovariancancersymp.org

12th International Symposium
ADVANCED Optimal Therapy. Update
Valencia, 22nd February 2019

Andrés Poveda
Initia Oncology, Hospital Quirónsalud, Valencia, Spain

Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

DIRECTORS
www.valencia-ovariancancersymp.org

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

SCIENTIFIC COMMITTEE
Andrés Cervantes (ESMO,GEICO)
Antonio González (ESMO,GEICO)
Andrés Poveda (ESMO,GEICO)
Jan B. Vermorken (ESMO,GEICO)

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

SCIENTIFIC COMMITTEE
Andrés Cervantes (ESMO,GEICO)
Antonio González (ESMO,GEICO)
Andrés Poveda (ESMO,GEICO)
Jan B. Vermorken (ESMO,GEICO)
Welcome

SESSION 2: TREATMENT OF PRIMARY DISEASE
Chairs:
Jonathan A. Ledermann, UCL Cancer Institute, University College, London, UK
Luis Chiva, Clínica Universidad de Navarra, Madrid, Spain

11:15-11:35
How to manage lymph nodes in ovarian cancer in 2019
Philipp Harter, Kliniken Essen-Mitte, Essen, Germany

11:35-11:55
Can we predict who lives long with ovarian cancer?
Michael A. Bookman, Kaiser Permanente Northern California, (CA), USA

11:55-12:15
Landscape of systemic therapy for ovarian cancer in 2019
Keiichi Fujiwara, Saitama Medical University, Saitama, Japan

12:15-12:35
Discussion

12:35-13:35
Does HIPEC improve survival in AOC?
Chairs:
Jan B. Vermorken, Antwerp University Hospital, Edegem, Belgium
Giovanni Scambia, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

PRO:
Gabe Sonke, Netherlands Cancer Institute, Amsterdam, The Netherlands

CONS:
Ignace Vergote, University Hospitals Leuven, European Union

13:15-13:35
Discussion

13:35-15:00
Lunch

SESSION 3: TREATMENT OF RECURRENT DISEASE
Chairs:
Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Paris, France
Ana Oaknin, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

15:00-15:20
Who needs surgery?
Jalid Sehouli, Charité University of Medicine, Berlin, Germany

15:20-15:40
Do all patients need systemic therapy?
Michael Friedlander, The Prince of Wales Hospital, Randwick, Australia

15:40-16:10
Landscape of systemic therapy for recurrent ovarian cancer in 2019
Sandro Pignata, NIRCCS National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

16:10-16:30
Discussion

16:30-17:00
Coffee break

SESSION 4: NEW DEVELOPMENTS
Chairs:
Mansoor Mirza, Copenhagen University Hospital, Copenhagen, Denmark
Andrés Redondo, Hospital Universitario La Paz, Madrid, Spain

17:00-17:20
Immunotherapy in Ovarian Cancer: Still promising?
Antonio González, Clínica Universidad de Navarra, Madrid, Spain

17:20-17:40
New Strategies in Ovarian Cancer Treatment
Erica Ball, National Cancer Institute, Bethesda, USA

17:40-18:00
Remarks and Conclusions
Andrés Poveda, Initia Oncology, Hospital Quirónsalud, Valencia, Spain
Valencia, 22nd February 2019

SESSION 3: TREATMENT OF PRIMARY DISEASE

Chairs: Michael Birrer, Massachusetts General Hospital, Boston (MA), USA
         Jose A. López-Guerrero, Fundación Instituto Valenciano de Oncología, Valencia, Spain

09:45-10:05 Precision medicine in epithelial ovarian cancer
      Iain McNeish, Imperial College London, UK

09:45-10:05 The potential role of liquid biopsies in ovarian cancer
      Martin Widschwendter, University College London, UK

10:05-10:25 TILs and PD-L1 expression in ovarian cancer: What to do with it?
      George Coukos, University of Lausanne, Switzerland

10:25-10:45 Discussion

10:45-11:15 Coffee Break

SESSION 3: TREATMENT OF RECURRENT DISEASE

Chairs: Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Paris, France
         Ana Oaknin, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

15:00-15:20 Who needs surgery?
      Jalid Sehouli, Charité University of Medicine, Berlin, Germany

15:20-15:40 Do all patients need systemic therapy?
      Michael Friedlander, The Prince of Wales Hospital, Randwick, Australia

15:40-16:10 Landscape of systemic therapy for recurrent ovarian cancer in 2019
      Sandro Pignata, NIRCCS National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

16:10-16:30 Discussion

16:30-17:00 Lunch

SESSION 4: NEW DEVELOPMENTS

Chairs: Mansoor Mirza, Copenhagen University Hospital, Copenhagen, Denmark
       Andrés Redondo, Hospital Universitario La Paz, Madrid, Spain

17:00-17:20 Immunotherapy in Ovarian Cancer: Still promising?
      Andrés Redondo, Hospital Universitario La Paz, Madrid, Spain

17:20-17:40 New Strategies in Ovarian Cancer Treatment
      Elke Eleb, National Cancer Institute, Bethesda (MD), USA

17:40-18:00 Remarks and Conclusions
      Andrés Poveda, Initia Oncology, Hospital Quirónsalud, Valencia, Spain
SESSION 1: TRANSLATIONAL RESEARCH
Chairs:
Michael Birrer, Massachusetts General Hospital, Boston (MA), USA
Jose A. López-Guerrero, Fundación Instituto Valenciano de Oncología, Valencia, Spain
09:25-09:45
Precision medicine in epithelial ovarian cancer
Iain McNeish, Imperial College London, UK
09:45-10:05
The potential role of liquid biopsies in ovarian cancer
Martin Widschwendter, University College London, UK
10:05-10:25
TILs and PD-L1 expression in ovarian cancer: What to do with it?
George Coukos, University of Lausanne, Switzerland
10:25-10:45
Discussion

SESSION 2: TREATMENT OF PRIMARY DISEASE
Chairs:
Jonathan A. Ledermann, UCL Cancer Institute, University College, London, UK
Luis Chiva, Clínica Universidad de Navarra, Madrid, Spain
11:15-11:35
How to manage lymph nodes in ovarian cancer in 2019
Philipp Harter, Kliniken Essen-Mitte, Essen, Germany
11:35-11:55
Can we predict who lives long with ovarian cancer?
Michael A. Bookman, Kaiser Permanente Northern California, CA, USA
11:55-12:15
Landscape of systemic therapy for ovarian cancer in 2019
Keiichi Fujiwara, Saitama Medical University, Saitama, Japan
12:15-12:35
Discussion

SESSION 3: TREATMENT OF RECURRENT DISEASE
Chairs:
Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Paris, France
Ana Oaknin, Vall d´Hebron University Hospital. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
15:00-15:20
Who needs surgery?
Jalid Sehouli, Charité University of Medicine, Berlin, Germany
15:20-15:40
Do all patients need systemic therapy?
Michael Friedlander, The Prince of Wales Hospital, Randwick, Australia
15:40-16:10
Landscape of systemic therapy for recurrent ovarian cancer in 2019
Sandro Pignata, NIRCCS National Cancer Institute “Fondazione G. Pascale”, Naples, Italy
16:10-16:30
Discussion

SESSION 4: NEW DEVELOPMENTS
Chairs:
Mansoor Mirza, Copenhagen University Hospital, Copenhagen, Denmark
Andrés Redondo, Hospital Universitario La Paz, Madrid, Spain
17:00-17:20
Immunotherapy in Ovarian Cancer: Still promising?
Antonio González, Clínica Universidad de Navarra, Madrid, Spain
17:20-17:40
New Strategies in Ovarian Cancer Treatment
Elise C. Kohn, National Cancer Institute, Bethesda (MD), USA
17:40-18:00
Remarks and Conclusions
Andrés Poveda, Initia Oncology, Hospital Quirónsalud, Valencia, Spain
VENUE
Palau de la Música  
Iturbi Meeting Room  
Paseo de la Alameda, 30 · 46023 Valencia, Spain

SYMPOSIUM SECRETARIAT
E-mail: aocsymp2019@doctaforum.com  
Phone: +34 913 72 02 03  
Web: www.valencia-ovariancancersymp.org

12th International Symposium  
ADVANCED Optimal Therapy. Update  
Valencia, 22nd February 2019  

Andrés Poveda  
Initia Oncology, Hospital Quirónsalud, Valencia, Spain  

Jan B. Vermorken  
Antwerp University Hospital, Edegem, Belgium

DIRECTORS
www.valencia-ovariancancersymp.org

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education.